Cargando…

Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation

Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mengqi, Guo, Wenzhi, Zhang, Shuijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732630/
https://www.ncbi.nlm.nih.gov/pubmed/29302641
http://dx.doi.org/10.1097/IJ9.0000000000000049
_version_ 1783286742281879552
author Liu, Mengqi
Guo, Wenzhi
Zhang, Shuijun
author_facet Liu, Mengqi
Guo, Wenzhi
Zhang, Shuijun
author_sort Liu, Mengqi
collection PubMed
description Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated.
format Online
Article
Text
id pubmed-5732630
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-57326302018-01-02 Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation Liu, Mengqi Guo, Wenzhi Zhang, Shuijun Int J Surg Oncol (N Y) Review Articles Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated. Wolters Kluwer 2017-12 2017-11-16 /pmc/articles/PMC5732630/ /pubmed/29302641 http://dx.doi.org/10.1097/IJ9.0000000000000049 Text en Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of IJS Publishing Group Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
spellingShingle Review Articles
Liu, Mengqi
Guo, Wenzhi
Zhang, Shuijun
Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title_full Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title_fullStr Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title_full_unstemmed Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title_short Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
title_sort cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732630/
https://www.ncbi.nlm.nih.gov/pubmed/29302641
http://dx.doi.org/10.1097/IJ9.0000000000000049
work_keys_str_mv AT liumengqi cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation
AT guowenzhi cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation
AT zhangshuijun cancerimmunotherapyinpatientswithneworrecurrentmalignanciesafterlivertransplantation